Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

Blood (2025) 146 (Supplement 1): 3734.

https://doi.org/10.1182/blood-2025-3734

Published: 2025

Journal Articles

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Evgenii Shumilov, Débora-Michèle Grote Urtubey, Marcel Teichert, Maximilian Seib, Rebecca Wurm-Kuczera, Joseph Kauer, Friedrich-Linus Roessiger, Tobias Tix, Alexander Hölscher, Philipp Gödel, Christoph Brey, Paolo Mazzeo, Zoi Saxonis, Belana Kuhn, Vanja Zeremski, Franziska Brunner, Susanne Ghandili, Enver Aydilek, Markus Maulhardt, Philipp Nakov, Gregor Friedrich, Christian Schultze-Florey, Giuliano Filippini Velazquez, Igor Age Kos, Anna Ossami Saidy, Christoph Kimmich, Maika Klaiber-Hakimi, Philipp Berning, Andrea Kerkhoff, Bertram Glass, Isabelle Krämer, Lorenz Thurner, Mathias Lutz, Florian Heidel, Vladan Vucinic, Christiane Pott, Andreas Viardot, Gerald Wulf, Thomas Weber, Dimitrios Mougiakakos, Francis Ayuk, Udo Holtick, Sascha Dietrich, Niklas Gebauer, Ulf Schnetzke, Mathias Hänel, Martin Dreyling, Peter Dreger, Björn Chapuy, Fabian Müller, Bastian von Tresckow, Georg Lenz

Blood (2025) 146 (Supplement 1): 5473.

https://doi.org/10.1182/blood-2025-5473

Published: 2025

Journal Articles

Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification

Tim Richardson, Udo Holtick, Lukas Frenzel, Daniel Schütte, Clara Burkhard-Meier, Karl-Anton Kreuzer, Philipp Gödel, Michael Hallek, Christof Scheid

Blood (2025) 146 (Supplement 1): 2505.

https://doi.org/10.1182/blood-2025-2505

Published: 2025

Journal Articles

Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 367.

https://doi.org/10.1182/blood-2024-203291

Published: 2024

Journal Articles

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Blood (2024) 143 (6): 522–534.

https://doi.org/10.1182/blood.2023022020

Published: 2024

Includes: Supplemental data

Journal Articles

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Jan-Michel Heger, Julia Mattlener, Philipp Gödel, Hyatt Balke-Want, Noëlle Sieg, Nadine Kutsch, Kerstin Becker, Jonathan Weiss, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Blood (2022) 140 (Supplement 1): 3537–3538.

https://doi.org/10.1182/blood-2022-162420

Published: 2022

Journal Articles

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tatjana Holzer, Stefanie Biedermann, Inga Herfort, Birte Friedrichs, Silke Holtkamp, Linda Hanssens, Mario Assenmacher, Ulf Bethke, Dina Schneider, Stefan Miltenyi, Toon Overstijns, Christoph Schmid, Francis A. Ayuk, Christoph Scheid, Anja Jühling, Udo Holtick, Philipp Gödel, Peter Borchmann, Iris Bürger

Blood (2022) 140 (Supplement 1): 4581–4583.

https://doi.org/10.1182/blood-2022-164597

Published: 2022

Journal Articles

A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nadine Kutsch, Philipp Gödel, Udo Holtick, Anja Lohneis, Vladan Vucinic, Florentine Pia Altefrohne, Christin Schubert, Sandra Karitzky, Linda Hanssens, Mario Assenmacher, Iris Bürger, Murat Aktas, Peter Borchmann

Blood (2022) 140 (Supplement 1): 12980–12981.

https://doi.org/10.1182/blood-2022-168730

Published: 2022

Journal Articles

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Blood (2022) 140 (Supplement 1): 2411–2413.

https://doi.org/10.1182/blood-2022-165452

Published: 2022

Journal Articles

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Jan-Michel Heger, Claus Moritz Graef, Philipp Falderbaum, Philipp Gödel, Hyatt Balke-Want, Florian Simon, Noëlle Sieg, Jan-Hendrik Naendrup, Marie Anne-Catherine Neumann, Sarah Gillessen, Paul J Bröckelmann, Dennis A. Eichenauer, Peter Borchmann, Bastian Von Tresckow

Blood (2021) 138 (Supplement 1): 2531.

https://doi.org/10.1182/blood-2021-145283

Published: 2021

Journal Articles

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-136067

Published: 2020

Journal Articles

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Hyatt Balke-Want, MD, Philipp Gödel, MD, Nima Abedpour, PhD, Martin Peifer, PhD, Peter Borchmann, MD

Blood (2018) 132 (Supplement 1): 4119.

https://doi.org/10.1182/blood-2018-99-110600

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab

Real-world use of loncastuximab tesirine in heavily pretreated and high risk relapsed/refractory large B-cell lymphoma patients: German multicenter analysis

Upfront vs posttherapy allogeneic stem cell transplantation for high-risk myelodysplastic syndrome – a real-world analysis in the era of molecular risk stratification

Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase I Dose Finding Trial of MB-CART20.1 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Impact of Timing and Precision of Histopathological Diagnosis on Outcomes of Patients with Burkitt and High-Grade B-Cell Lymphoma

Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Clonal Evolution of a Mutation in PTPRA As a Potential Cause for Resistance Against Anti-CD19 Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with CTL019 in DLBCL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only